This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Unigene Laboratories" – news · newspapers · books · scholar · JSTOR (March 2012) (Learn how and when to remove this template message)
This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Unigene Laboratories" – news · newspapers · books · scholar · JSTOR (July 2020) (Learn how and when to remove this template message)
| Company type | Public |
|---|---|
| OTC Pink No Information: UGNEQ | |
| Industry | Biotechnology |
| Headquarters | , United States  |
Key people | Ashleigh Palmer, President and CEO Gregory T. Mayes, Esq., Vice President, Corporate Development and General Counsel Nozer Mehta, Ph.D., Vice President, Biological Research and Development Paul Shields, Ph.D., Vice President, Technology Transfer and Contract Manufacturing Services William Steinhauer, CPA Vice President, Finance |
| Website | www.unigene.com |
Unigene Laboratories (OTC:UGNE) was a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey.
The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.
Unigene filed for Chapter 7 bankruptcy on July 2, 2013 in the United States Bankruptcy Court of the District of New Jersey. The Chapter 7 case is being administered under case No. 13-24696.